期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 70, 期 5, 页码 1281-1284出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dku572
关键词
antimicrobial resistance; adaptive design; regulatory approval; narrow spectrum antibiotics; antibiotic pricing; antibacterial use
Drug licensing is changing. Previously, regulators prioritized the licensing of innovative drugs that fulfilled a high unmet medical need for a small number of patients, including orphan, cancer and HIV medicines. Alternatives to large and costly prospective, randomized, double-blind clinical trials have led to a more bespoke development, such as adaptive design studies. Regulators have recently agreed to include much-needed narrow-spectrum antibiotics, active against certain MDR bacteria, in this paradigm. The background to why big pharmaceutical companies have largely deserted the antibacterial research arena, and the proposals that are hoped to reinvigorate their interest, are presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据